Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Our goal is to enhance the lives of people living with these rare diseases.
Science
Seralutinib
Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Patients
The PROSERA Study
The PROSERA Study is a phase 3 clinical research study of seralutinib in adults with pulmonary arterial hypertension (PAH). Gossamer Bio has an unwavering and real commitment to the patient community. Our team aims to improve lives of patients through meaningful advances in the development of new therapies and an unwavering commitment to supporting patient communities across the globe.
Careers & Culture
Working at Gossamer
We are a team of highly dedicated, passionate individuals. We pride ourselves on a culture of respect, humility, transparency, dedication, collaboration and fun. Our ultimate mission is to improve the lives of patients with rare diseases.
